Roche Diagnostics Terminates Deal to Market Response Bio's Cardiovascular Panel | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Diagnostics has terminated a sales and distribution deal with Response Biomedical after the Canadian diagnostic test maker failed to get US regulatory clearance of its cardiovascular tests on its most current platform, Response Bio announced today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.